期刊文献+

百乐眠胶囊联合艾司西酞普兰片对失眠伴抑郁焦虑患者睡眠质量、不良情绪以及神经递质水平的影响 被引量:26

Effect of Bailemen Capsule Combined with Escitalopram Tablet on Sleep Quality,Bad Mood and Neurotransmitter Level of Insomnia Patients with Depression and Anxiety
原文传递
导出
摘要 目的:探讨百乐眠胶囊联合艾司西酞普兰片对失眠伴抑郁焦虑患者睡眠质量、不良情绪以及神经递质水平的影响。方法:选取2017年7月~2019年12月期间我院收治的失眠伴抑郁焦虑患者117例,将上述患者根据随机数字表法分为对照组(n=58,艾司西酞普兰片治疗)和研究组(n=59,百乐眠胶囊联合艾司西酞普兰片治疗),比较两组患者睡眠质量、不良情绪、多导睡眠图(PSG)参数、神经递质水平及不良反应。结果:研究组治疗2个月后的临床总有效率为93.22%(55/59),高于对照组的79.31%(46/58)(P<0.05)。两组治疗2个月后汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)以及匹兹堡睡眠质量指数(PSQI)评分、睡眠潜伏期、P物质(SP)均较治疗前降低,且研究组低于对照组(P<0.05)。两组治疗2个月后睡眠总时间、睡眠效率、神经肽Y(NPY)、5-羟色胺(5-HT)升高,且研究组高于对照组(P<0.05)。治疗期间研究组不良反应发生率较对照组降低(P<0.05)。结论:失眠伴抑郁焦虑患者经百乐眠胶囊联合艾司西酞普兰片治疗后,睡眠质量、不良情绪得到显著改善,同时还可有效改善血清神经递质水平,减少不良反应,临床应用效果确切。 Objective: To investigate the effect of Bailemen capsule combined with escitalopram tablet on sleep quality, bad mood and neurotransmitter level in insomnia patients with depression and anxiety. Methods: 117 insomnia patients with depression and anxiety who were admitted to our hospital from July 2017 to December 2019 were selected, they were randomly divided into control group(n=58, treated with escitalopram tablet) and study group(n=59, treated with Bailemian capsule and escitalopram tablet) by random number table method. The sleep quality, bad mood, polysomnography(PSG) parameters, neurotransmitter level and adverse reactions of the two groups were compared. Results: The total clinical effective rate of the study group was 93.22%(55/59), which was higher than 79.31%(46/58) of the control group(P<0.05). The scores of Hamilton anxiety scale(HAMA), Hamilton depression scale(HAMD) and Pittsburgh sleep quality index(PSQI), sleep latency and substance P(SP) of the two groups were lower than those before treatment, and the study group was lower than the control group(P<0.05). The total sleep time, sleep efficiency, neuropeptide Y(NPY), 5-hydroxytryptamine(5-HT) in the two groups increased at after 2 months of treatment, and the study group was higher than the control group(P<0.05). The incidence of adverse reactions in the study group was lower than that in the control group(P<0.05). Conclusion: After the treatment of insomnia patients with depression and anxiety with baile mian capsule and esitalopram tablet, the quality of sleep and bad mood are improved significantly, and the levels of serum neurotransmitter are also improved effectively, and the adverse reactions are reduced, the effect of clinical application is accurate.
作者 邹瑛 田道峰 侯亚婷 龙星颖 王慧玲 成敬 ZOU Ying;TIAN Dao-feng;HOU Ya-ting;LONG Xing-ying;WANG Hui-ling;CHENG Jing(Department of Pharmacy,People's Hospital of Wuhan University,Wuhan,Hubei,430060,China;Department of Neurosurgery,People's Hospital of Wuhan University,Wuhan,Hubei,430060,China;Department of Psychiatry,People's Hospital of Wuhan University,Wuhan,Hubei,430060,China)
出处 《现代生物医学进展》 CAS 2021年第8期1465-1468,1424,共5页 Progress in Modern Biomedicine
基金 湖北省卫生计生委指导性项目(WJ2017F1259)。
关键词 百乐眠胶囊 失眠伴抑郁焦虑 艾司西酞普兰片 睡眠质量 不良情绪 神经递质 Bailemen capsule Insomnia with depression and anxiety Escitalopram tablet Sleep quality Bad mood Neurotransmitter
  • 相关文献

参考文献11

二级参考文献91

  • 1孟庆云.开拓中医学的睡眠理论研究开拓[J].中国中医基础医学杂志,1997,3(S3):3-4. 被引量:4
  • 2张斌,荣润国.失眠的认知行为治疗[J].中国心理卫生杂志,2004,18(12):882-884. 被引量:42
  • 3各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33022
  • 4Moller H J, Bandelow B, Bauer M, et al. DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, con- sequences-part 2: bipolar disorders, schizophrenia spectrum dis- orders, anxiety disorders, obsessive-compulsive, disorders] trau-ma- and stressor-related disorders, personality disorders, sub- stance-related and addictive disorders, neurocognitive disorders [J]. Eur Arch Psychiatry Clin Neurosci, 2015, 265(2): 87-106.
  • 5van Os J, Tamminga C. Deconstructing psychosis[J]. Schizophr Bull, 2007, 33(4): 861-862.
  • 6Tandon R. The nosology of schizophrenia: toward DSM-5 and ICD-1 l[J]. Psychiatr Clin North Am, 2012, 35(3): 557-569.
  • 7Heckers S, Barch DM, Bustillo J, et al. Structure of the psychotic disorders classification in DSM-5[J]. Schizophr Res, 2013, 150 (1): 11-14.
  • 8Maier W. Do schizoaffective disorders exist at all?[J]. Acta Psy- chiatr Scan& 2006, 113(5): 369-371.
  • 9Boonstra N, Klaassen R, Sytema S, et al. Duration of untreated psychosis and negative symptoms-a systematic review and me- ta-analysis of individual patient data[J]. Schizophr Res, 2012, 142(1-3): 12-19.
  • 10Pagsberg AK. Schizophrenia spectrum and other psychotic disor- ders[J]. Eur Child Adolesc Psychiatry, 2013, 22(Suppl 1 ):S3-S9.

共引文献196

同被引文献340

引证文献26

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部